Part I – Video illustrates the DNA fragmentation, end repair, and 3’ end A-tailing process in the Universal NGS Complete Workflow Solution.
Part II - Video illustrates the adapter ligation process and the purification of the ligated library in the Universal NGS Complete Workflow Solution.
Part III - Video illustrates the pre-capture PCR of the ligated library and its purification in the Universal NGS Complete Workflow Solution.
Part IV - Video illustrates the hybridization process with design specific baits in the Universal NGS Complete Workflow Solution.
Part V – Video illustrates the post-capture PCR of the hybridized samples, and the final pooling for sequencing in the Universal NGS Complete Workflow Solution.
This video illustrates the key steps for enzymatic DNA fragmentation prior to library preparation using the SureSeq™ NGS Library Preparation Kit for solid tumor samples.
This video illustrates the key steps for AMPure® purification using the SureSeq™ NGS Library Preparation Kit for solid tumor samples.
This video illustrates the key steps for Dynabeads™ M270 Streptavidin magnetic bead preparation using the SureSeq™ NGS Library Preparation Kit for solid tumor samples.
This video illustrates the key steps for hybrid capture using the SureSeq™ NGS Library Preparation Kit for solid tumor samples.
This video illustrates the key steps for post-hybridization bead washing using the SureSeq™ NGS Library Preparation Kit for solid tumor samples.
Learn about Interpret, OGT’s powerful and easy-to-use next generation sequencing analysis solution, designed to work seamlessly with SureSeq and CytoSure NGS panels.
Learn how easy it is to upload sample FASTQ files into OGT’s Interpret software and use them to create a batch for data analysis.
Learn how simply you can navigate round your analysis batch results and generate batch reports up front of variant analysis.
Learn how Interpret software creates easy to navigate displays of QC metrics to help users access the performance of their sequencing runs.
Find out how to view analysis results by variants and explore using this feature in the Interpret software.
Discover how to navigate and modify the Variant results page, selecting aberration types and customizing data analysis displays and tables with the many options available.
In this AMP 2023 session, Dr. Klaus Metzeler describes the current technology landscape and prognostic relevance of minimal residual disease (MRD) detection and demonstrates his experience using NGS-based MRD detection in AML, including OGT’s NGS-based SureSeq™ Myeloid MRD Panel.
In this AMP 2022 session, Dr. McCready examines mutation profiles in AML and MDS from a large Southern Ontario cohort utilizing two NGS panels, including OGT’s SureSeq Myeloid™ NGS panel.
In this AMP 2022 session, Dr. Capo-Chichi shares his experience evaluating KMT2A- PTDs detection utilizing three technologies; the SureSeq™ NGS panel with KMT2A specific probes engineered by OGT, an MLPA assay, and Optical Genome Mapping (OGM).
Presented at GLGC 2022, hear how our customers Dr. Peter Sabatini and Dr. Graeme Quest streamlined their CLL research and utilized OGT’s SureSeq™ CLL + CNV NGS panel to detect CNVs in five chromosomal regions as well as SNVs and indels in key genes implicated in CLL.
Dr Fortin will talk about transitioning from microarray to the SureSeq™ CLL + CNV NGS panel, and how the SureSeq CLL + CNV NGS Panel delivers a comprehensive genomic profile for each CLL sample using a single workflow, including trisomy 12, 11q, 13q and 17p deletions.
Dr. McCready will examine the utility of a CytoSure® Constitutional NGS panel to identify relevant variants in families with reduced penetrance or uncertain CNVs. Findings from this pilot cohort were compared to data from chromosome microarray analysis to evaluate feasibility of the NGS platform for copy number detection and its utility in identifying SNVs acting synergistically with CNVs to affect phenotype.
Dr. Tucker shares her experience of how OGT’s NGS panel, SureSeq™ CLL + CNV, has streamlined her laboratory workflow and enabled the detection of various aberrations in key genes implicated in CLL progression, including SNVs, indels, and CNVs. This alleviates the burden of running multiple assays and delivers comprehensive results with a single NGS analysis.
Dr. McCready will compare a hybridization-based NGS panel versus single analyte and amplicon-based NGS assays for somatic mutation testing in myeloid malignancies, from her experience with OGT’s SureSeq myPanel™ Custom Myeloid - 49 gene plus panel.
In this webinar learn how the SureSeq™ CLL + CNV NGS Panel alleviates the burden of running multiple assays and streamlines your CLL research to deliver a comprehensive genomic profile for each CLL sample using a single NGS assay.
Watch this webinar and learn how the CytoSure® Constitutional NGS solution, which delivers CNV analysis with excellent concordance with the ‘gold standard’ method, aCGH, can make the transition from arrays to NGS as painless as possible.